Slides
Page 1
Hui a Tau Annual Shareholders Meeting 20 October 2026
Page 2
Disclaimer and important notice Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading distributor of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to subscribe for, or an offer of, shares, securities or financial products to any person, in any country or the basis for a contract, financial advice, other advice or recommendation to conclude any transaction for the purchase or sale of any security, loan or other instrument. This presentation has not been independently verified. Neither Rua nor any of its directors, officers, shareholders, advisors, agents or employees make any representation or warranty as to the accuracy or completeness of the information contained in this presentation and those parties shall have no liability for any statement, opinion, information or matters arising out of, contained in, or for any omissions from, or failure to correct or update any information in, this presentation or any other communications transmitted to you in relation to this presentation.
Page 3
How to Participate in Virtual/ Hybrid Meetings and Ask a Question Shareholder & Proxyholder Q & A Participation Online Questions If you have a question to submit during the live meeting, please select the Q & A tab on the right half of your screen at anytime. Type your question into the field and press submit. Your question will be immediately submitted to the moderator. Help The Q & A tab can also be used for immediate help. If you need assistance, please submit your query in the same manner as typing a question and a Computershare representative will respond directly to you.
Page 4
How to Participate in Virtual/ Hybrid Meetings and Vote Shareholder & Proxyholder Voting • Once the voting has been opened, the resolutions and voting options will allow voting. • To vote, simply click on the Vote tab, and select your voting direction from the options shown on the screen. • Your vote has been cast when the tick appears. • To change your vote, select ‘Change Your Vote’.
Page 5
Board of Directors Te Poari Ringatohu Anna Stove Chair More than 25 years’ global executive and board experience across healthcare, biotechnology and regulated scientific sectors. Panapa Ehau Executive Director, Co - Founder Co-founder of a number of social enterprises. Holds governance roles across numerous for-profit and charitable organisations. Teresa Ciprian Non-Executive Director Global expertise in innovation, commercialisation, marketing and business development in the primary sector. Tony Barclay Non-Executive Director Over 30 years’ experience in business, with 25 years of healthcare experience. Chair of the Audit, Finance and Risk Committee.
Page 6
Agenda Rarangi take 01 Company overview and Chair’s address 02 Chief Executive’s presentation 03 Annual Results presentation 04 Shareholder questions 05 Ordinary resolutions 06 General business Ordinary resolutions 1 Auditor’s remuneration 2 Re-election of Anna Stove as Director 3 Re-election of Panapa Ehau as Director 4 Re-election of Antony Barclay as Director 5 Election of Qi (Keith) Zhou as Director 6 Issue of new Ordinary Shares (if required)
Page 7
01 Company overview and Chair’s address Te tirohanga whanui o te kamupene me te korero a te Heamana
Page 8
Germany | Australia | Canada Aotearoa , NZ | UK | Czechia Rua’s differentiated, capital -light model Unique Genetics Rua’s point of difference Trusted cultivation and manufacturing partners provide scalable capacity close to market, at lower per-unit cost and without the high capital costs of GMP infrastructure. Built around unique genetics, market access and trusted partners
Page 9
FY26 Key Achievements summary Financial results and progress across our markets Commercial momentum $2.9m Total revenue +53% Cost control $3.1m Operating loss ↓7% Shareholder support $2.3m Equity raised Commercial milestones Customer revenue grew 71% to $2.6m. Canada First live cannabis clone export — the first known legal export of live cannabis genetics from New Zealand. Czechia Rua’s first product launched through partner Motagon. Australia & New Zealand Expanded NZ product portfolio and grew sales with leading Australian clinic chains. Since year end: Five further products were approved in Aotearoa New Zealand in July 2026.Subsequent activity UK sales and distribution agreement with Curaleaf Five further products approved in Aotearoa New Zealand
Page 10
UK agreement: a significant commercial milestone A major step forward for Rua’s export-led strategy LARGEST EXPORT AGREEMENT TO DATE $10m+ EXPECTED REVENUE over the initial two-year term A significant route to market Access to an established UK clinic and distribution channel. Evidence of the strategy’s potential A major export opportunity delivered through Rua’s capital-light model. Working capital enables delivery Inventory and working capital must be funded ahead of sales and cash receipts.
Page 11
Approximately $1mill raised from recent rights issue Working capital is the immediate constraint — not infrastructure $1m Rights Offer outcome • Funds inventory and working capital ahead of sales, particularly to fulfil the UK agreement. • Supports demand in Australia and Aotearoa, New Zealand- alongside opportunities in Canada and Czechia.
Page 12
02 Chief Executive Officer’s presentation Te whakatakotoranga o te Kaiwhakahaere Matua
Page 13
FY26: An overview Tirohanga whanui $2.9m Total Revenue 71% Revenue growth 6 Markets $0.3m $1.9m $2.9m FY24 FY25 FY26
Page 14
Global progress Kokiri ki te ao Aotearoa New Zealand Grew market share; five new product approvals Australia Almost doubled revenue through key clinic chains United Kingdom Largest export agreement to date, signed July 2026 Germany Expanded product range at a time of market change Canada First export of live clones to Apollo Green Czechia First products launched through Motagon Six markets, one platform Australia | Aotearoa New Zealand | Germany | United Kingdom | Czechia | Canada
Page 15
Aotearoa, New Zealand is our home market • Revenue almost tripled to $1.30m (FY25: $0.44m), with increased market share. • New products introduced, including a medical vaporising device. • Five further products approved by the regulator in July 2026. Sales revenue $0.44m $1.30m FY25 FY26
Page 16
Australia is the second largest market • Revenue almost doubled to $1.03m (FY25: $585k), with margin also almost doubling. • World’s second largest medicinal cannabis market, estimated at $1.4b. • Grew market share through strong clinic chain relationships, despite the regulator’s review. Sales revenue $0.58m $1.03m FY25 FY26
Page 17
Germany is the largest market • World’s largest market, estimated at $2b; a government review and oversupply made FY26 challenging. • Expanded our range with NZ grown genetics; progressing talks with large clinic chains. • Delivered cost reduced by close to 50%. Estimated market size $0.4b $1.4b $2.0b United Kingdom Australia Germany
Page 18
United Kingdom is the fastest growing market • Fastest growing market: prescriptions doubled in the past year; estimated at $400m. • July 2026: sales and distribution agreement signed with a leading UK clinic chain. • Working with NZ cultivators to bring Rua’s genetics to the UK. ~$10m Expected sales over initial two -year term
Page 19
Czechia: We are one of the early entrants • April 2025 reform allowed GPs to prescribe medicinal cannabis. • First product launched through distribution partner Motagon. • Early-stage market (~$10m); modest revenue expected to build through FY27. Sept 2025 First product launched
Page 20
Canada: A first foothold for Rua genetics • April 2026: first known legal export of live cannabis genetics from New Zealand. • Four varieties shipped as clones to Apollo Green in Ontario, establishing a genetic bank. • Creates further options for distribution and revenue. $5–6b Estimated annual adult -use market
Page 21
We continue to support 52 patients per month through our Compassionate Access Programme 52 patients supported each month
Page 22
Our Scholarship Programme is inspiring rangatahi In FY26 we awarded 14 scholarships to local rangatahi 14 Scholarships in FY26 67 Recipients since 2020 8 School trips funded 3 Internships
Page 23
Rua’s FY26 GHG report Te ripoata GHG o Rua mo FY26 19% ↓ Scope 1 and 2 emissions reduced by 19% (FY25: 39, FY26: 32 tCO2 -e) 14% ↓ Scope 1 emissions reduced by 14%, with a smaller vehicle fleet 22% ↓ Scope 2 emissions reduced by 22%, as NZ’s grid emissions fell Scope 1 and 2 emissions (tCO2-e) 51 41 39 32 FY23 FY24 FY25 FY26
Page 24
The next generation of Rua products INITIAL PHASE MDMA distribution PharmAla agreement: Rua imports, distributes and sells pharmaceutical-grade MDMA in Aotearoa. Medsafe has approved two psychiatrists to prescribe for PTSD. Capital-light. RESEARCH PROGRAMME Tū Wairua Psilocybin-containing mushrooms for methamphetamine addiction, led by the Rangiwaho Marae community. Rua contributes cultivation and regulatory capability. RESEARCH PROGRAMME Wairuakōhu Radula liverwort, native to Aotearoa, produces compounds understood to act on cannabinoid receptors. Partners include IO Limited. RESEARCH PROGRAMME Cytisine from kōwhai A native source of an established smoking-cessation medicine, with a substantial clinical evidence base including New Zealand-led trials. No revenue from the research programmes is assumed in FY27 or FY28. Rua contributes capability, not capital.
Page 25
Our plans for FY27 are to continue growing sales UK DISTRIBUTION AGREEMENT ~$10m over two years NEW PRODUCTS Five new approvals in Aotearoa NZ NEW MARKETS Canada
Page 26
03 FY26 financial commentary Nga korero mo nga putea
Page 27
Profit & loss Nga korero mo nga putea Rua’s annual financial results for the year ended 30 June 2026. $2.6m Revenue from customers $2.9m Total revenue and other income -$3.4m Loss before tax Strong revenue growth
Page 28
Balance sheet Nga korero mo nga putea Rua’s annual financial results for the year ended 30 June 2026. $534k Cash and investments $7.17m Total assets $2.92m Total liabilities $4.25m Net assets Rua requires further capital
Page 29
Cashflow Nga korero mo nga putea Rua’s annual financial results for the year ended 30 June 2026. $2.96m Net cash outflow from operating activities $0.01m Net cash inflow from investing activities $3.24m Net cash inflow from financing activities Investing in growth
Page 30
Operating loss is narrowing Nga korero mo nga putea Operating loss before net financing costs FY25 $3.30m Operating loss FY26 $3.07m Operating loss
Page 31
Sales revenue is growing Nga korero mo nga putea Annual revenue from customers $0.09m $1.51m $2.58m FY24 FY25 FY26
Page 32
04 Shareholder questions Nga patai a nga kaipupuri hea
Page 33
05 Ordinary resolutions Whakataunga noa
Page 34
Resolution One That the Board be authorised to fix the auditor’s remuneration.
Page 35
Resolution Two That Anna Stove be re -elected as a Director of Rua
Page 36
Resolution Three That Panapa Ehau be re - elected as a Director of Rua
Page 37
Resolution Four That Antony Barclay be re - elected as a Director of Rua
Page 38
Resolution Five That Qi (Keith) Zhou be elected as a Director of Rua • Nominated within the Director Nomination Period • Would not be an Independent Director if elected • The Board supports his election
Page 39
Resolution Six That the Directors are authorised to issue New Shares if required • Up to 69,635,032 shares • At a price of not less than $0.03 per share • At any time during the 12 months following approval
Page 40
06 General business Nga take hakirikiri